Diagnostics (Jan 2023)

Upstaging and Downstaging in Gliomas—Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System

  • Oana Gabriela Trifănescu,
  • Raluca Alexandra Trifănescu,
  • Radu Mitrică,
  • Dan Mitrea,
  • Ana Ciornei,
  • Mihai Georgescu,
  • Ioana Butnariu,
  • Laurenția Nicoleta Galeș,
  • Luiza Șerbănescu,
  • Rodica Maricela Anghel,
  • Mihai-Andrei Păun

DOI
https://doi.org/10.3390/diagnostics13020197
Journal volume & issue
Vol. 13, no. 2
p. 197

Abstract

Read online

In 2021, the 5th edition of the WHO Classification of Tumors of the Central Nervous System (WHO-CNS5) was published as the sixth volume of the international standard for brain and spinal cord tumor classification. The most remarkable practical change in the current classification involves grading gliomas according to molecular characterization. IDH mutant (10%) and IDH wild-type tumors (90%) are two different entities that possess unique biological features and various clinical outcomes regarding treatment response and overall survival. This article presents two comparative cases that highlight the clinical importance of these new classification standards. The first clinical case aimed to provide a comprehensive argument for determining the IDH status in tumors initially appearing as low-grade astrocytoma upon histologic examination, thus underlining the importance of the WHO-CNS5. The second case showed the implications of the histologic overdiagnosis of glioblastoma using the previous classification system with a treatment span of 7 years that proceeded through full-dose re-irradiation up to metronomic therapy. The new WHO-CNS5 classification significantly impacted complex neurooncological cases, thus changing the initial approach to a more precise therapeutic management.

Keywords